Drug Type CAR-T |
Synonyms- |
Target |
Mechanism BCMA modulators(B-cell maturation protein modulators), SLAMF7 modulators(SLAM family member 7 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plasma cell myeloma refractory | Phase 1 | CN | 25 Mar 2020 | |
Relapse multiple myeloma | Phase 1 | CN | 25 Mar 2020 |
NCT04662099 (ASH2022) Manual | Phase 1 | 16 | (jolmeyldit) = not observed zqwjvhhclk (lfgbgfjblg ) | Positive | 15 Nov 2022 | ||
NCT04662099 (EHA2022) Manual | Phase 1 | 13 | chemotherapy+CS1-BCMA CAR-T cells | (bzfujzkezd) = ceamaorzrt oraayswwbl (yamuiuawfq ) View more | Positive | 12 May 2022 |